- Forums
- ASX - By Stock
- PER
- FDA review re Sarepta 21/6/24 expanded gene therapy
FDA review re Sarepta 21/6/24 expanded gene therapy, page-9
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $117.2M |
Open | High | Low | Value | Volume |
13.5¢ | 14.0¢ | 13.0¢ | $168.5K | 1.260M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 633259 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 874939 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 633259 | 0.130 |
3 | 1437000 | 0.125 |
8 | 91409 | 0.120 |
5 | 1062287 | 0.115 |
5 | 322225 | 0.110 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 874939 | 7 |
0.140 | 531203 | 7 |
0.145 | 205238 | 8 |
0.150 | 973514 | 8 |
0.155 | 122559 | 2 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online